These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15710801)

  • 1. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.
    Kucher N; Leizorovicz A; Vaitkus PT; Cohen AT; Turpie AG; Olsson CG; Goldhaber SZ
    Arch Intern Med; 2005 Feb; 165(3):341-5. PubMed ID: 15710801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
    Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.
    Alikhan R; Cohen AT; Combe S; Samama MM; Desjardins L; Eldor A; Janbon C; Leizorovicz A; Olsson CG; Turpie AG;
    Arch Intern Med; 2004 May; 164(9):963-8. PubMed ID: 15136304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.
    Kahn SR; Panju A; Geerts W; Pineo GF; Desjardins L; Turpie AG; Glezer S; Thabane L; Sebaldt RJ;
    Thromb Res; 2007; 119(2):145-55. PubMed ID: 16516275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalteparin versus unfractionated heparin in critically ill patients.
    ; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
    N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism in the medically ill patient: a call to action.
    Bergmann JF; Kher A
    Int J Clin Pract; 2005 May; 59(5):555-61. PubMed ID: 15857352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
    Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
    J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overweight, obesity, and the risk of recurrent venous thromboembolism.
    Eichinger S; Hron G; Bialonczyk C; Hirschl M; Minar E; Wagner O; Heinze G; Kyrle PA
    Arch Intern Med; 2008 Aug; 168(15):1678-83. PubMed ID: 18695082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of venous thromboembolism in medically ill patients: a clinical update.
    Turpie AG; Leizorovicz A
    Postgrad Med J; 2006 Dec; 82(974):806-9. PubMed ID: 17148703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended thromboprophylaxis reduces incidence of postoperative venous thromboembolism in laparoscopic bariatric surgery.
    Magee CJ; Barry J; Javed S; Macadam R; Kerrigan D
    Surg Obes Relat Dis; 2010; 6(3):322-5. PubMed ID: 20510295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis.
    Holmström M; Aberg W; Lockner D; Paul C
    Thromb Haemost; 1999 Oct; 82(4):1222-6. PubMed ID: 10544902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
    Schulman S; Lundström T; Wålander K; Billing Clason S; Eriksson H
    Thromb Haemost; 2005 Oct; 94(4):820-4. PubMed ID: 16270637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.